from at least one time point (day 30 (d30) or day 100 (d100)) after allo-SCT was available. Data on d30 and d100 had been documented for 41 patients and for 59 patients, respectively. Patients consented to the use of laboratory and clinical data for research studies. The study was performed in accordance with the Declaration of Helsinki. Patient characteristics are depicted in Table 1 . During a median follow-up of 13 months, 19 out of 76 patients (25%) developed haematological relapse post transplant (median, 23 weeks from HSCT; range, 7-40 weeks) and 22 out of 76 patients (29%) died. The cause of death was relapse in 16 out of 22 (73%) patients and TRM in 6 (27%; fatal GVHD: n ¼ 1, severe infection/sepsis: n ¼ 4, other causes: n ¼ 1). Median levels of CD10 þ CD19 þ cells by MFC were 0.06% on d30 (mean 0.25%; range, 0-2.4%) and 1.55% on d100 (mean, 2.13%; range, 0-12.4%). Primary hypothesis in this retrospective analysis from one single centre was that levels of CD10 þ CD19 þ cells on d100 might be associated with 1-year OS. In the group below the mean CD10 þ CD19 þ cells of 2.13%, the Kaplan-Meier estimate of 1-year OS±s.e. was 69±9% (median±s.e. ¼ 89±10 weeks; 95% confidence interval (CI) ¼ 68-109 weeks), which was worse when compared with the group above the mean with a 1-year OS ± s.e. of 83 ± 15% (median ± s.e. ¼ 96 ± 8 weeks; 95% CI ¼ 81-111 weeks). This difference was statistically significant (Relative Risk (RR) ¼ 0.124; 95% CI ¼ 0.016-0.967; P ¼ 0.046; Cox regression analysis, Figure 1a ). The effect of low versus high CD10 þ CD19 þ cells measured at d100 on EFS was similar. Oneyear EFS was 60±10% in the group with lower CD10 þ CD19 þ counts on d100 versus 96 ± 4% in the group with higher counts (RR ¼ 0.200; 95% CI ¼ 0.045-0.896; P ¼ 0.035, Figure 1b In a logistic regression analysis, BM CD10 þ CD19 þ cells on d100 showed a positive correlation with peripheral blood CD19 þ CD20 þ cells (r 2 ¼ 0.6751, P ¼ 1.6E-22). The mature peripheral blood T-lymphocyte subsets that we assessed (CD3 þ CD4 þ and CD3 þ CD8 þ cells) did not correlate with BM CD10 þ CD19 þ cells, neither on d30 nor on d100, nor did CD10 þ CD19 þ cells on d30 show a correlation with any subset measured on d100. We saw no correlation between CD10 þ CD19 þ cells at d30 and leukocyte engraftment kinetics (r 2 ¼ 0.003, data not shown). We and others 9 show a favourable prognostic impact of increased BM CD10 þ CD19 þ cells in patients with myeloid malignancies 100 days after allo-SCT. However, the findings presented in this retrospective analysis on 76 patients from one centre need independent prospective confirmation, as selection bias and sample size are limitations of our study. As we were not able to demonstrate an independent prognostic value of the haematogone level in multivariate analysis, it also remains to be clarified whether this was due to the limited number of patients we studied or whether the haematogone level is closely linked to distinct disease characteristics. An impact of haematogones on OS of patients with AML after allo-SCT in other settings, for example, those where B-cell depleting agents are used, 10 remains to be addressed, too. Subgroups of AML and MDS patients, for example, based on cytogenetics or molecular risk factors with distinctive haematogone kinetics, should be identified in larger cohorts. Low levels of haematogones at d100 might represent an epiphenomenon of residual leukemia cells. In conclusion, a higher haematogone level in the post-transplant period is prognostically favourable for patients with myeloid malignancies. The underlying causes for this observation and the weight of the prognostic impact of the haematogone level in comparison with other prognostic factors in the post-transplant period should be explored in independent studies.
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